Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.48 |
| ▸ | HCK | P08631 | 15/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 14/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | TOP2A | P11388 | 1/20 | 0.37 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17008504 | 0.90 | MAPK14 (0.49) | MAPK14HCKMAPK12SRC | |
| SCHEMBL17017622 | 0.88 | SRC (0.47) | MAPK14HCKMAPK12SRCCYP2C9 | |
| SCHEMBL17017630 | 0.87 | MAPK14 (0.46) | MAPK14HCKMAPK12SRCAAK1 | |
| SCHEMBL29711992 | 0.87 | MAPK14 (0.46) | MAPK14HCKMAPK12SRCAAK1 | |
| SCHEMBL17008543 | 0.86 | MAPK14 (0.45) | MAPK14HCKMAPK12SRCCYP2C9 | |
| SCHEMBL17008589 | 0.85 | MAPK14 (0.44) | MAPK14HCKMAPK12SRCCYP2C9 | |
| SCHEMBL17017553 | 0.83 | MAPK14 (0.44) | MAPK14HCKMAPK12SRCGSK3A | |
| SCHEMBL28578481 | 0.82 | HCK (0.39) | MAPK14HCKMAPK12SRC | |
| SCHEMBL31086831 | 0.82 | MAPK14 (0.46) | MAPK14HCKMAPK12SRC | |
| SCHEMBL29711834 | 0.81 | MAPK14 (0.46) | MAPK14HCKMAPK12SRCCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2021-10-12 | — | — | US | disclosed |
| EP-3418279-B1 | DRY POWDER PHARMACEUTICAL FORMULATION | RESPIVERT LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-10294216-B2 | Pyrazolyl ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| US-20180118719-A1 | PYRAZOLYL UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9884845-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-02-06 | — | — | US | disclosed |
| US-20170057945-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-03-02 | — | — | US | disclosed |
| WO-2015121660-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294216-B2 | Pyrazolyl ureas as kinase inhibitors | MAP3K1, MAP3K2, MAP3K8 | MAPK14 18/4885HCK 773/4885MAPK12 43/4885 |
| US-20180118719-A1 | PYRAZOLYL UREAS AS KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K7 | MAPK14 16/4885HCK 553/4885MAPK12 37/4885 |
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | MAPK14 12/4885HCK 730/4885MAPK12 37/4885 |
| US-20170057945-A1 | NOVEL COMPOUNDS | MAPK1, MAPK6, MAPKAPK2 | MAPK14 4/4885HCK 2965/4885MAPK12 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.